4
41
8
9
. Bapiro T, Egnell A, Hasler J, Masimirembwa C (2001) Appli- 26. Constantino L, Paixao P, Moreira R, Portela M, Do Rosario
cation of higher throughput screening (HTS) inhibition assays
to evaluate the interaction of antiparasitic drugs with cyto-
chrome P450s. Drug Metab Dispos 29:30–35
. Bapiro T, Andersson T, Otter C, Hasler J, Masimirembwa C
(
V, Iley J (1999) Metabolism of primaquine by liver homogenate
fractions. Evidence for monoamine oxidase and cytochrome
P450 involvement in the oxidative deamination of primaquine
to carboxyprimaquine. Exp Toxicol Pathol 51:299–303
2002) Cytochrome P450 1A1/2 induction by antiparasitic 27. Karbwang J, Davis T, Looareesuwan S, Molunto P, Bunnag D,
drugs: dose-dependent increase in ethoxyresorufin O-de-
ethylase activity and mRNA caused by quinine, primaquine
and albendazole in HeG2 cells. Eur J Clin Pharmacol
White N (1993) A comparison of the pharmacokinetic and
pharmacodynamic properties of quinine and quinidine in
healthy Thai males. Br J Clin Pharmacol 35:265-271
5
8:537–542
28. Zhao X, Yokoyama H, Chiba K, Wanwimolruk S, Ishizaki T
(1996) Identification of human cytochrome P450 isoforms in-
volved in the 3-hydroxylation of quinine by human liver mi-
crosomes and nine recombinant human cytochromes P450.
J Pharmacol Exp Ther 279:1327–1334
1
1
0. Houston J (1994) Utility of in vitro drug metabolism data in
predicting in vivo metabolic clearance. Biochem Pharmacol
4
1. Obach R (1999) Prediction of human clearance of twenty-nine
7:1469–1479
drugs from hepatic microsomal intrinsic clearance data: an 29. Robson R, Bailey R, Sharman J (1984) Tinidazole pharmaco-
examination of in vitro half-life approach and nonspecific
binding to microsomes. Drug Metab Dispos 27:1350–1359
2. Ito K, Iwatsubo T, Kanamitsu S, Nakajima Y, Sugiyama Y
kinetics in severe renal failure. Clin Pharmacokinet 9:88–94
30. Giao P, Vries P (2001) Pharmacokinetic interactions of anti-
malarial agents. Clin Pharmacokinet 40:343–373
1
(1998) Quantitative prediction of in vivo drug clearance and 31. Lee I, Hufford C (1990) Metabolism of antimalarial sesqui-
drug interactions from in vitro data on metabolism, together
terpene lactones. Pharmacol Ther 48:345–355
with binding and transport. Ann Rev Pharmacol Toxicol 32. Projean D, Baune B, Farinotti R, Flinois J, Beaune P, Taburet
3
8:461–499
A, Ducharme J (2003) In vitro metabolism of chloroquine:
Identification of CYP2C8, CYP3A4, and CYP2D6 as the main
isoforms catalysing N-desethylchloroquine formation. Drug
Metab Dispos 31:748–754
1
1
1
3. Houston J, Carlile D (1997) Prediction of hepatic clearance
from microsomes, hepatocytes, and liver slices. Drug Metab
Rev 29:891–922
4. Crespi C (1995) Xenobiotic-metabolizing human cells as tools 33. Iwatsubo T, Hirota N, Ooie T, Suzuki H, Shimada N, Chiba K,
for pharmacological and toxicological research. Adv Drug Res
6:179–235
5. Nakajima M, Nakamara S, Tokudome S, Shimada N,
Ishizaki T, Green C, Tyson C, Sugiyama Y (1997) Prediction of
in vitro drug metabolism in the human liver from in vitro
metabolims data. Pharmacol Ther 73:147–171
2
Yamazaki H, Yokoi T (1999) Azelastine N-demethylation by 34. Carlile D, Hakooz N, Bayliss M, Houston J (1999) Microsomal
cytochrome P-450 (CYP)3A4, CYP2D6, and CYP1A2 in prediction of in vivo clearance of CYP2C9 substrates in
human liver microsomes: evaluation of approach to predict humans. Br J Clin Pharmacol 47:625–635
the contribution of multiple CYPs. Drug Metab Dispos 35. Clarke S, Jeffrey P (2001) Utility of metabolic stability
2
7:1381–1391
6. Obach R, Baxter J, Liston T, Silber B, Jones B, MacIntyre F,
screening: comparison of in vitro and in vivo clearance.
Xenobiotica 31:591–598
Rance D, Wastall P (1997) The prediction of human pharma- 36. May D, Porter J, Uetrecht J, Wilkinson G, Branch R (1990)
1
cokinetic parameters from preclinical and in vitro metabolism
data. J Pharmacol Exp Ther 283:46–58
7. White N, Looareesuwan S, Edwards G, Phillips R, Karbwang
The contribution of N-hydroxylation and acetylation to dap-
sone pharmacokinetics in normal subjects. Clin Pharmacol
Ther 48:619–627
1
1
J, Nicholl D, Bunch C, Warrell D (1987) Pharmacokinetics of 37. Svensson U, Ashton M (1999) Identification of the human
intravenous amodiaquine. Br J Clin Pharmacol 23:127–135
8. Li X, Bjorkman A, Andersson T, Ridderstro M,
Masimirembwa C (2002) Amodiaquine clearance and its 38. Coulet M, Dacasto M, Eeckhoutte C, Larrieu G, Sutra J,
cytochrome P450 enzymes involved in the in vitro metabolism
of artemisinin. Br J Clin Pharmacol 48:528–535
¨
¨
m
metabolism to N-desethylamodiaquine is mediated by
CYP2C8: a new high affinity and turnover enzyme specific
probe substrate. J Pharmacol Exp Ther 300:399–407
Alvinerie M, Mace K, Pfeifer A, Galtier P (1998) Identification
of human and rabbit cytochromes P450 1A2 as major isoforms
involved in thiabendazole 5-hydroxylation. Fundam Clin
Pharmacol 12:225–235
1
2
9. Davis T, Phuong H, Ilett K, Hung N, Batty K, Phuong V,
Powell S, Thien H, Binh T (2001) Pharmacokinetics and 39. Rawden H, Kokwaro G, Ward S, Edwards G (2000) Relative
pharmacodynamics of intravenous artesunate in severe falci-
parum malaria. Antimicrob Agents Chemother 45:181–186
0. Walker O, Salako L, Alvan G, Ericsson O, Sjoqvist F (1987)
contribution of cytochrome P450 and flavin-containing
monooxygenases to the metabolism of albendazole by human
liver microsomes. Br J Clin Pharmacol 49:313–322
The disposition of chloroquine in healthy Nigerians after 40. Winter H, Wang Y, Unadkat J (2000) CYP2C8/9 mediate
single intravenous and oral doses. Br J Clin Pharmacol
3:295–301
1. Ducharme J, Farinotti R (1996) Clinical pharmacokinetics and 41. Bronner U (1994) Pharmacokinetics of pentamidine: focus on
dapsone N-hydroxylation at clinical concentrations of dapsone.
Drug Metab Dispos 28:865–868
2
2
2
metabolism of chloroquine. Clin Pharmacokinet 31:257–274
2. Pieters F, Zuidema J (1987) The absolute oral bioavailability of
dapsone in dogs and humans. Int J Clin Pharmacol Ther
Toxicol 25:396–400
3. Mitra A, Thummel K, Kalhorn T, Kharasch E, Unadkat J,
Slattery J (1995) Metabolism of dapsone to its hydroxylamine
the treatment of trypanosoma gambiense sleeping sickness.
Thesis, Karolinska Institute, Huddinge University Hospital,
Stockholm
42. Ducharme J, Baune B, Taburet A, Farinotti R (1996) Chlo-
roquine metabolism in human liver microsomes. Exp Toxic
Pathol 48:345
2
2
by CYP2E1 in vitro and in vivo. Clin Pharmacol Ther 58:556– 43. Jewell H, Maggs J, Harrison A, O’Neill P, Ruscoe J, Park B
5
66
(1995) Role of hepatic metabolism in the bioactivation and
detoxication of amodiaquine. Xenobiotica 25:199–217
M, Rombo L (1995) Pharmacokinetics and adverse reactions 44. Na-Bangchang K, Vanijanonta S, Karbwang J (1995) Plasma
4. Bronner U, Gustafsson L, Doua F, Ericsson O, Miezan T, Rais
after a single dose of pentamidine in patients with Trypano-
soma gambiense sleeping sickness. Br J Clin Pharmacol 39:289–
concentrations of praziquantel during the therapy of neuro-
cysticercosis with praziquantel, in the presence of antiepileptics
and dexamethasone. Southeast Asian J Trop Med Public
Health 26:120–123
2
5. Mihaly G, Ward S, Edwards G, Nicholl D, Orme M, Breck-
95
2
enridge A (1985) Pharmacokinetics of primaquine in man. I. 45. Vazquez M, Jung H, Sotelo J (1987) Plasma levels of pra-
Studies of the absolute bioavailability and effects of dose size.
Br J Clin Pharmacol 19:745–750
ziquantel decrease when dexamethosone is given simulta-
neously. Neurology 37:1561–1562